Bristol-Myers Squibb’s revenue trends
In 2Q17, Bristol-Myers Squibb (BMY) generated revenues of around $5.1 billion, which reflected ~6% growth on a year-over-year (or YoY) basis and ~4% growth on a quarter-over-quarter basis.
In 2Q17, Bristol-Myers Squibb’s revenue growth was primarily driven by growth in sales of Opdivo and Eliquis. In 2Q17, Opdivo and Eliquis witnessed growth of ~42% and ~51% on a YoY basis. In 2Q17, Bristol-Myers Squibb reported net earnings of ~$922.0 million compared to $1.2 billion in 2Q16.
In 2Q17, Bristol-Myers Squibb generated revenues of ~$2.8 billion in the US market, which reflected ~7% growth on a YoY basis. The US market contributed ~56% of Bristol-Myers Squibb’s net revenues in 2Q17. In 2Q17, Bristol-Myers Squibb reported revenues of ~$1.1 billion and ~$963.0 million from Europe and the rest of the world, respectively.
In 2Q17, Bristol-Myers Squibb reported diluted earnings per share (or EPS) of $0.56 compared to $0.69 in 2Q16.
The chart above represents the revenue trajectory of Bristol-Myers Squibb from 1Q16 to 2Q17, as well as analysts’ estimates of 3Q17 and 4Q17. To learn more about Bristol-Myers Squibb’s valuations after 2Q17, please read How BMY Is Valued following Its 2Q17 Earnings.
In 2Q17, Bristol-Myers Squibb reported marketing, selling, and administrative (or MS&A) expenses and research and development (or R&D) expenses of around $1.2 billion and $1.7 billion, respectively, compared to $1.2 billion and $1.3 billion, respectively, in 2Q16.
In 2Q17, Bristol-Myers Squibb reported total expenses of around $3.8 billion compared to $3.3 billion in 2Q16.
Bristol-Myers Squibb’s peers in the oncology drug market include Novartis (NVS), Merck (MRK), Roche Holding (RHHBY), Johnson & Johnson, AbbVie, Celgene, Eli Lilly, and Pfizer. Bristol-Myers Squibb comprises ~0.45% of the portfolio holdings of the SPDR S&P 500 ETF (SPY).